Promising Therapy for AL (Immunoglobulin Light Chain) Amyloidosis

Systebryl™ is our lead compound currently in Phase 1 human clinical trials to address the unmet therapeutic need of patients suffering from a rare disease known as AL Amyloidosis. This disease impacts approximately 10,000 to 20,000 people world-wide every year.

Systebryl™ is believed to be the first drug to prevent and cause reduction and clearance of AL amyloid deposits in the body (heart and kidney). Systebryl™ is being developed by ProteoTech as the world's first and only drug to reduce and eliminate amyloid deposits in heart (and other organs) in AL amyloid patients. AL amyloidosis is a type of cancer due to plasma cell (bone marrow) abnormalities that leads to insoluble amyloid deposits in heart, kidney and other tissues. Massive AL amyloid deposits in heart leads to a marked thickening of the ventricles and eventual heart failure and death. The median survival time in stage III AL amyloid patients is only 4-6 months from diagnosis. The only treatment at this time is chemotherapy which does not work in approximately 40% of AL patients.

ProteoTech will continue to develop Systebryl™ and request Orphan Drug Status from the FDA which will provide extended patent protection due to smaller population of people afflicted with this disease.